Skip to content
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
  • Pipeline
    • SurVaxM
  • Clinical Trials
  • About
    • Leadership Team
  • News
  • Contact
Pipeline
SurVaxM
Clinical Trials
About
Leadership Team
News
Contact
Read more about the article MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma
Cape Egmont Lighthouse and Taranaki Mount on background, New Zealand

MimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma

  • Post author:mimivax
  • Post published:November 15, 2021
  • Post category:Uncategorized

November 12, 2021 - MimiVax has received a “Study May Proceed” notification from the US FDA to initiate a Phase 2b clinical trial of SurVaxM in newly diagnosed glioblastoma -Completed Phase…

Continue ReadingMimiVax, LLC Receives FDA Approval to Initiate a New Phase 2b Clinical Study for the Treatment of Newly Diagnosed Glioblastoma

Recent Posts

  • MimiVax Announces Positive Interim Analysis in Ongoing SurVaxM Clinical Trial 
  • MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment
  • US FDA awards Supplemental Orphan Drug Designation to SurVaxM to now include treatment of Malignant Glioma
  • MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma 

Recent Comments

    Archives

    • February 2025
    • January 2025
    • May 2024
    • January 2024
    • October 2023
    • December 2022
    • November 2022
    • February 2022
    • November 2021
    • November 2019
    • October 2019
    • May 2019
    • March 2018
    • August 2017
    • July 2016
    • September 2015
    • April 2015

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    MimiVax, Inc.

    [email protected]

    Elm & Carlton Streets
    Buffalo, NY 14263

    Back to top
    Twitter Linkedin Youtube